this article describes the acelrx's fiyrtg quarter and Tetraphase acquisition conference call. the acelrx's co-promotion agreement is a strategic strategic alignment for the acelrx and a commercial commercial team. the acquisition is consistent with the plan to expand and diversify the company's product portfolio and better leverage its expertise and infrastructure. together, we are a stronger and more efficient organization representing two innovative products that will improve patient care by fulfilling unmet needs in healthcare institutions.